Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash & Equivalents: 2023-2025

Historic Cash & Equivalents for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $401.6 million.

  • Monte Rosa Therapeutics' Cash & Equivalents rose 219.83% to $401.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.6 million, marking a year-over-year increase of 219.83%. This contributed to the annual value of $381.0 million for FY2024, which is 61.14% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Cash & Equivalents of $401.6 million as of Q3 2025, which was up 33.49% from $300.9 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Cash & Equivalents ranged from a high of $401.6 million in Q3 2025 and a low of $47.0 million during Q2 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $125.6 million (2024), whereas its average is $195.2 million.
  • Data for Monte Rosa Therapeutics' Cash & Equivalents shows a peak YoY soared of 235.91% (in 2025) over the last 5 years.
  • Over the past 3 years, Monte Rosa Therapeutics' Cash & Equivalents (Quarterly) stood at $236.4 million in 2023, then spiked by 61.14% to $381.0 million in 2024, then skyrocketed by 219.83% to $401.6 million in 2025.
  • Its Cash & Equivalents stands at $401.6 million for Q3 2025, versus $300.9 million for Q2 2025 and $335.1 million for Q1 2025.